Analyst Linda Bolton Weiser maintains a Buy rating on elf Beauty's stock rating with an unchanged 12-18-month $23 price target and five-year price target of $40.
Investors punished elf's stock after finding fault with the company's announcement that its products would be included in thousands of Walgreens Boots Alliance Inc (NYSE: WBA)'s stores, Bolton Weiser said in a Monday report.
Elf said the inclusion will help it achieve its 6-8-percent 2018 sales growth guidance rather than exceed it, as many might have expected, the analyst said. Some Street commentators are going so far as to suggest elf will miss its 2018 guidance, a concept Bolton Weiser said is "way off base."
The reality is that reaching 6-8-percent sales guidance is a rare feat in the beauty space, the analyst said. This level of growth implies the company is far from "low quality" and warrants a multiple expansion, she said.
The stock's 10.7x EBITDA multiple is a discount to multiple peers with poorer growth rates, Bolton Weiser said. For example, industry giant Estee Lauder Companies Inc (NYSE: EL) trades at a 15.1 EBITDA multiple, but with a long-term sales growth target of 6-8 percent.
Elf's stock is trading at an attractive valuation at which it could be acquired, the analyst said. Recent deals in the space include Estee Lauder's acquisition of Too Faced for five times sales, which, if applied to elf's estimated 2018 sales of $289 million, implies a $1.01-billion takeout valuation. This also implies a 40-percent premium to elf's equity market value and a 16-percent premium over its enterprise value, Bolton Weiser said.
Shares of e.l.f. Beauty were rallying 5.58 percent to $16.09 at the time of publication Monday.
Why Walgreens Is Important For E.L.F. Beauty Products
Deutsche Bank Likes Estee Lauder After 'Exceptionally Strong' Quarter
Latest Ratings for ELF
|May 2018||Oppenheimer||Initiates Coverage On||Outperform|
|Mar 2018||Morgan Stanley||Downgrades||Equal-Weight||Underweight|
View More Analyst Ratings for ELF
View the Latest Analyst Ratings
See more from Benzinga
- 3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley
- Analyst: The Bullish Case For Axon Isn't Based On Taser Sales Alone
- Adamis Pharma Soars 60% Amid New Partnership With Novartis To Commercialize Symjepi
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.